News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genzyme Corporation (GENZ) and Veracyte, Inc. Announce Expanded U.S. Availability of the Afirma┬« Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis


4/16/2012 10:08:23 AM

CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that the Afirma® Thyroid FNA Analysis, an innovative approach for improved thyroid nodule diagnosis, is now available to patients across the United States.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES